Audentes Therapeutics (NASDAQ:BOLD) and Twist Bioscience (NASDAQ:TWST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.
Earnings & Valuation
This table compares Audentes Therapeutics and Twist Bioscience’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Audentes Therapeutics||N/A||N/A||-$128.82 million||($3.40)||-10.80|
|Twist Bioscience||$25.43 million||26.28||-$71.23 million||($25.51)||-0.93|
This table compares Audentes Therapeutics and Twist Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
97.4% of Audentes Therapeutics shares are held by institutional investors. Comparatively, 22.7% of Twist Bioscience shares are held by institutional investors. 6.6% of Audentes Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and price targets for Audentes Therapeutics and Twist Bioscience, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Audentes Therapeutics currently has a consensus target price of $39.99, indicating a potential upside of 8.94%. Twist Bioscience has a consensus target price of $25.99, indicating a potential upside of 9.06%. Given Twist Bioscience’s stronger consensus rating and higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Audentes Therapeutics.
Twist Bioscience beats Audentes Therapeutics on 6 of the 10 factors compared between the two stocks.
About Audentes Therapeutics
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.